Annalz
2021-12-20
MRNA gonna to fly to another new high
Moderna Says Covid-19 Booster Dose Works Against Omicron Variant in Lab Tests<blockquote>Moderna 表示 Covid-19 加强剂量在实验室测试中可对抗奥密克戎变种</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":693650502,"tweetId":"693650502","gmtCreate":1640015670540,"gmtModify":1640015671054,"author":{"id":3577089953267281,"idStr":"3577089953267281","authorId":3577089953267281,"authorIdStr":"3577089953267281","name":"Annalz","avatar":"https://static.tigerbbs.com/ffd285ab6189bb61da4b48c3e149eedc","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":45,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>MRNA gonna to fly to another new high</p></body></html>","htmlText":"<html><head></head><body><p>MRNA gonna to fly to another new high</p></body></html>","text":"MRNA gonna to fly to another new high","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693650502","repostId":1141595302,"repostType":4,"repost":{"id":"1141595302","kind":"news","pubTimestamp":1639997819,"share":"https://www.laohunote.com/m/news/1141595302?lang=zh_CN&edition=full","pubTime":"2021-12-20 18:56","market":"us","language":"en","title":"Moderna Says Covid-19 Booster Dose Works Against Omicron Variant in Lab Tests<blockquote>Moderna 表示 Covid-19 加强剂量在实验室测试中可对抗奥密克戎变种</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141595302","media":"WSJ","summary":"ModernaInc. said a third dose of its Covid-19 vaccine increased immune responses against the Omicron","content":"<p>ModernaInc. said a third dose of its Covid-19 vaccine increased immune responses against the Omicron coronavirus variant compared with two doses in lab tests, signaling the shot could still offer protection despite the variant’s mutations.</p><p><blockquote>ModernaInc. 表示，在实验室测试中，与两剂相比，第三剂 Covid-19 疫苗增强了对奥密克戎冠状病毒变种的免疫反应，这表明尽管变种发生了突变，但注射仍能提供保护。</blockquote></p><p> The findings, reported by Moderna on Monday, were the latest positive—though preliminary—results from lab tests suggesting boosters can protect against the worrisome new strain.</p><p><blockquote>Moderna 周一报道的这些发现是实验室测试的最新阳性（尽管是初步的）结果，表明加强剂可以预防令人担忧的新菌株。</blockquote></p><p> The Cambridge, Mass., company said the authorized dosage of its booster shot increased levels of immune-system agents known as neutralizing antibodies against Omicron about 37 times more than pre-boost levels.</p><p><blockquote>马萨诸塞州剑桥。该公司表示，其加强注射的授权剂量使被称为中和奥密克戎抗体的免疫系统制剂的水平比加强前的水平增加了约37倍。</blockquote></p><p> Neutralizing antibodies are among the first soldiers that the immune system deploys to battle invaders like the coronavirus.</p><p><blockquote>中和抗体是免疫系统部署来对抗冠状病毒等入侵者的第一批士兵之一。</blockquote></p><p> “What we showed is when you boost, you get a good brisk increase in antibody levels and they would be correlated with protection,” Moderna Chief Medical Officer Paul Burton said in an interview.</p><p><blockquote>“Moderna 首席医疗官保罗-伯顿（Paul Burton）在接受采访时说：”我们的研究表明，当你加强抗体时，抗体水平会急剧上升，这与保护作用有关。</blockquote></p><p> The authorized booster shot is half the dose level used for each of the first two shots of the vaccine.</p><p><blockquote>授权的加强注射是疫苗前两次注射中每次注射剂量水平的一半。</blockquote></p><p> Together with similar results from lab testing by Pfizer Inc.and partner BioNTech SE,Moderna’s findings suggest Covid-19 vaccines designed to fight the virus strain that was predominant during 2020may still hold up well against variants such as Omicron that are significantly mutated.</p><p><blockquote>结合辉瑞公司（Pfizer Inc.）和合作伙伴 BioNTech SE 的类似实验室测试结果，Moderna 的研究结果表明，旨在对抗 2020 年流行的病毒株病毒的 Covid-19 疫苗可能仍然能很好地抵抗奥密克戎病毒等明显变异的变种。</blockquote></p><p> Yet people would have to get a booster shot on top of the primary series of vaccinations to gain the protection.</p><p><blockquote>然而，人们必须在初级系列疫苗接种的基础上注射加强针才能获得保护。</blockquote></p><p> When Omicron emerged, researchers and health authorities expressed concern that the variant could evade vaccines because it has many mutations to the spike protein targeted by the shots.</p><p><blockquote>当奥密克戎病毒出现时，研究人员和卫生当局表示担心这种变异可能会逃避疫苗，因为它对疫苗所针对的刺突蛋白有许多突变。</blockquote></p><p> Adding to their fears was research indicating that Omicron is less susceptible to two doses of Moderna’s and other Covid-19 vaccines.</p><p><blockquote>研究表明，奥密克戎对两剂 Moderna 和其他 Covid-19 疫苗的敏感性较低，这更让他们感到担忧。</blockquote></p><p> Lab-test results released last week by a team of researchers from Moderna, the National Institute of Allergy and Infectious Diseases and Duke University showed that two doses of Moderna’s vaccine had significantly reduced neutralization activity against Omicron.</p><p><blockquote>来自 Moderna、美国国家过敏和传染病研究所和杜克大学的研究小组上周公布的实验室测试结果显示，两剂 Moderna 疫苗已显著降低了对奥密克戎病毒的中和活性。</blockquote></p><p> The findings from Pfizer-BioNTech and Moderna are based on lab tests, not the clinical trials in volunteers that are considered more definitive.</p><p><blockquote>辉瑞-BioNTech和Moderna的发现是基于实验室测试，而不是被认为更确定的志愿者临床试验。</blockquote></p><p> Moderna disclosed its booster results, which haven’t been peer reviewed and published in a scientific journal, in a news release. The company plans to share the data with government health officials.</p><p><blockquote>Moderna 在一份新闻稿中披露了其助推器结果，但这些结果尚未经过同行评审并发表在科学杂志上。该公司计划与政府卫生官员分享这些数据。</blockquote></p><p> The Omicron variant was identified in late November in southern Africa and has now spread to many countries, including the U.S.</p><p><blockquote>奥密克戎变种于11月下旬在南部非洲被发现，现已传播到包括美国在内的许多国家。</blockquote></p><p> Early studies suggest it spreads faster and reinfects people more easily than other variants and it evades vaccine-induced antibodies to a greater degree. It isn’t known yet whether Omicron causes more or less severe Covid-19.</p><p><blockquote>早期研究表明，与其他变种相比，它传播速度更快，更容易再次感染人，并且在更大程度上逃避疫苗诱导的抗体。目前尚不清楚奥密克戎病毒会导致更严重还是更严重的 Covid-19。</blockquote></p><p> The new data may reinforce calls by public-health officials for vaccinated people to get booster shots. In the U.S., only about 29.5% of fully vaccinated people have received booster doses, according to the Centers for Disease Control and Prevention.</p><p><blockquote>新数据可能会加强公共卫生官员对接种疫苗的人进行加强注射的评级。根据美国疾病控制和预防中心的数据，在美国，只有大约29.5%的完全接种疫苗的人接受了加强剂量。</blockquote></p><p> Moderna also found that using a full dose for the third shot packed a more powerful punch than the authorized booster dose. A third full dose increased neutralizing antibodies against Omicron about 83 times more than pre-boost levels.</p><p><blockquote>Moderna 还发现，第三次注射使用全剂量比授权的加强剂量具有更强大的冲击力。第三次全剂量增加了针对奥密克戎的中和抗体，比加强前水平高出约83倍。</blockquote></p><p> Dr. Burton said government regulators may want to consider recommending the higher-dose boosters to increase protection, at least among people at higher risk of more severe Covid-19.</p><p><blockquote>伯顿博士说，政府监管机构可能会考虑推荐更高剂量的加强剂来增加保护，至少在更严重的新冠肺炎风险较高的人群中是这样。</blockquote></p><p> However, in a separate study, Moderna said people receiving the higher-dose booster had more frequent adverse reactions than those who received the lower dose.</p><p><blockquote>然而，在另一项研究中，Moderna 表示，接受高剂量加强剂的人比接受低剂量加强剂的人出现更频繁的不良反应。</blockquote></p><p> Dr. Burton said the reactions include headache, fever and joint stiffness and should be balanced against the potential benefits of a higher-dose booster.</p><p><blockquote>伯顿博士说，这些反应包括头痛、发烧和关节僵硬，应该与高剂量加强剂的潜在益处相平衡。</blockquote></p><p> Moderna also tested other experimental booster shots that target older variants, including Delta, and found they provided a comparable boost to antibody levels against Omicron as its original vaccine booster shot.</p><p><blockquote>Moderna 还测试了其他针对旧变种（包括 Delta）的实验性加强注射，发现它们对奥密克戎病毒的抗体水平的增强作用与其原始疫苗加强注射相当。</blockquote></p><p> Pfizer and BioNTech said a third dose of their Covid-19 vaccine increased neutralizing antibodies against Omicron compared with just two doses.</p><p><blockquote>辉瑞和BioNTech表示，与仅接种两剂相比，第三剂新冠肺炎疫苗增加了针对奥密克戎的中和抗体。</blockquote></p><p> Given the speed of Omicron’s spread, Moderna said its near-term priority will be to continue making booster shots of its original vaccine available.</p><p><blockquote>鉴于奥密克戎病毒的传播速度，Moderna公司表示，其近期的首要任务将是继续提供原有疫苗的加强注射。</blockquote></p><p> It said it would keep working on an Omicron-specific booster shot, in case it is needed. Moderna expects to start clinical trials of an Omicron-specific booster in early 2022.</p><p><blockquote>该公司表示，如果需要的话，将继续研发针对奥密克戎的加强注射。Moderna 预计将于 2022 年初开始奥密克戎特异性增强剂的临床试验。</blockquote></p><p> The new data on Moderna’s booster and Omicron came from lab tests that mix blood samples from vaccinated people with an engineered virus that resembles the Omicron variant. The tests were conducted at Duke University Medical Center labs that were established by the National Institute of Allergy and Infectious Diseases, Moderna said.</p><p><blockquote>有关 Moderna 加强剂和奥密克戎的新数据来自实验室测试，该测试将接种疫苗者的血液样本与一种类似奥密克戎变种的工程病毒混合在一起。Moderna说，这些测试是在杜克大学医学中心实验室进行的，该实验室由国家过敏和传染病研究所建立。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Says Covid-19 Booster Dose Works Against Omicron Variant in Lab Tests<blockquote>Moderna 表示 Covid-19 加强剂量在实验室测试中可对抗奥密克戎变种</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Says Covid-19 Booster Dose Works Against Omicron Variant in Lab Tests<blockquote>Moderna 表示 Covid-19 加强剂量在实验室测试中可对抗奥密克戎变种</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">WSJ</strong><span class=\"h-time small\">2021-12-20 18:56</span>\n</p>\n</h4>\n</header>\n<article>\n<p>ModernaInc. said a third dose of its Covid-19 vaccine increased immune responses against the Omicron coronavirus variant compared with two doses in lab tests, signaling the shot could still offer protection despite the variant’s mutations.</p><p><blockquote>ModernaInc. 表示，在实验室测试中，与两剂相比，第三剂 Covid-19 疫苗增强了对奥密克戎冠状病毒变种的免疫反应，这表明尽管变种发生了突变，但注射仍能提供保护。</blockquote></p><p> The findings, reported by Moderna on Monday, were the latest positive—though preliminary—results from lab tests suggesting boosters can protect against the worrisome new strain.</p><p><blockquote>Moderna 周一报道的这些发现是实验室测试的最新阳性（尽管是初步的）结果，表明加强剂可以预防令人担忧的新菌株。</blockquote></p><p> The Cambridge, Mass., company said the authorized dosage of its booster shot increased levels of immune-system agents known as neutralizing antibodies against Omicron about 37 times more than pre-boost levels.</p><p><blockquote>马萨诸塞州剑桥。该公司表示，其加强注射的授权剂量使被称为中和奥密克戎抗体的免疫系统制剂的水平比加强前的水平增加了约37倍。</blockquote></p><p> Neutralizing antibodies are among the first soldiers that the immune system deploys to battle invaders like the coronavirus.</p><p><blockquote>中和抗体是免疫系统部署来对抗冠状病毒等入侵者的第一批士兵之一。</blockquote></p><p> “What we showed is when you boost, you get a good brisk increase in antibody levels and they would be correlated with protection,” Moderna Chief Medical Officer Paul Burton said in an interview.</p><p><blockquote>“Moderna 首席医疗官保罗-伯顿（Paul Burton）在接受采访时说：”我们的研究表明，当你加强抗体时，抗体水平会急剧上升，这与保护作用有关。</blockquote></p><p> The authorized booster shot is half the dose level used for each of the first two shots of the vaccine.</p><p><blockquote>授权的加强注射是疫苗前两次注射中每次注射剂量水平的一半。</blockquote></p><p> Together with similar results from lab testing by Pfizer Inc.and partner BioNTech SE,Moderna’s findings suggest Covid-19 vaccines designed to fight the virus strain that was predominant during 2020may still hold up well against variants such as Omicron that are significantly mutated.</p><p><blockquote>结合辉瑞公司（Pfizer Inc.）和合作伙伴 BioNTech SE 的类似实验室测试结果，Moderna 的研究结果表明，旨在对抗 2020 年流行的病毒株病毒的 Covid-19 疫苗可能仍然能很好地抵抗奥密克戎病毒等明显变异的变种。</blockquote></p><p> Yet people would have to get a booster shot on top of the primary series of vaccinations to gain the protection.</p><p><blockquote>然而，人们必须在初级系列疫苗接种的基础上注射加强针才能获得保护。</blockquote></p><p> When Omicron emerged, researchers and health authorities expressed concern that the variant could evade vaccines because it has many mutations to the spike protein targeted by the shots.</p><p><blockquote>当奥密克戎病毒出现时，研究人员和卫生当局表示担心这种变异可能会逃避疫苗，因为它对疫苗所针对的刺突蛋白有许多突变。</blockquote></p><p> Adding to their fears was research indicating that Omicron is less susceptible to two doses of Moderna’s and other Covid-19 vaccines.</p><p><blockquote>研究表明，奥密克戎对两剂 Moderna 和其他 Covid-19 疫苗的敏感性较低，这更让他们感到担忧。</blockquote></p><p> Lab-test results released last week by a team of researchers from Moderna, the National Institute of Allergy and Infectious Diseases and Duke University showed that two doses of Moderna’s vaccine had significantly reduced neutralization activity against Omicron.</p><p><blockquote>来自 Moderna、美国国家过敏和传染病研究所和杜克大学的研究小组上周公布的实验室测试结果显示，两剂 Moderna 疫苗已显著降低了对奥密克戎病毒的中和活性。</blockquote></p><p> The findings from Pfizer-BioNTech and Moderna are based on lab tests, not the clinical trials in volunteers that are considered more definitive.</p><p><blockquote>辉瑞-BioNTech和Moderna的发现是基于实验室测试，而不是被认为更确定的志愿者临床试验。</blockquote></p><p> Moderna disclosed its booster results, which haven’t been peer reviewed and published in a scientific journal, in a news release. The company plans to share the data with government health officials.</p><p><blockquote>Moderna 在一份新闻稿中披露了其助推器结果，但这些结果尚未经过同行评审并发表在科学杂志上。该公司计划与政府卫生官员分享这些数据。</blockquote></p><p> The Omicron variant was identified in late November in southern Africa and has now spread to many countries, including the U.S.</p><p><blockquote>奥密克戎变种于11月下旬在南部非洲被发现，现已传播到包括美国在内的许多国家。</blockquote></p><p> Early studies suggest it spreads faster and reinfects people more easily than other variants and it evades vaccine-induced antibodies to a greater degree. It isn’t known yet whether Omicron causes more or less severe Covid-19.</p><p><blockquote>早期研究表明，与其他变种相比，它传播速度更快，更容易再次感染人，并且在更大程度上逃避疫苗诱导的抗体。目前尚不清楚奥密克戎病毒会导致更严重还是更严重的 Covid-19。</blockquote></p><p> The new data may reinforce calls by public-health officials for vaccinated people to get booster shots. In the U.S., only about 29.5% of fully vaccinated people have received booster doses, according to the Centers for Disease Control and Prevention.</p><p><blockquote>新数据可能会加强公共卫生官员对接种疫苗的人进行加强注射的评级。根据美国疾病控制和预防中心的数据，在美国，只有大约29.5%的完全接种疫苗的人接受了加强剂量。</blockquote></p><p> Moderna also found that using a full dose for the third shot packed a more powerful punch than the authorized booster dose. A third full dose increased neutralizing antibodies against Omicron about 83 times more than pre-boost levels.</p><p><blockquote>Moderna 还发现，第三次注射使用全剂量比授权的加强剂量具有更强大的冲击力。第三次全剂量增加了针对奥密克戎的中和抗体，比加强前水平高出约83倍。</blockquote></p><p> Dr. Burton said government regulators may want to consider recommending the higher-dose boosters to increase protection, at least among people at higher risk of more severe Covid-19.</p><p><blockquote>伯顿博士说，政府监管机构可能会考虑推荐更高剂量的加强剂来增加保护，至少在更严重的新冠肺炎风险较高的人群中是这样。</blockquote></p><p> However, in a separate study, Moderna said people receiving the higher-dose booster had more frequent adverse reactions than those who received the lower dose.</p><p><blockquote>然而，在另一项研究中，Moderna 表示，接受高剂量加强剂的人比接受低剂量加强剂的人出现更频繁的不良反应。</blockquote></p><p> Dr. Burton said the reactions include headache, fever and joint stiffness and should be balanced against the potential benefits of a higher-dose booster.</p><p><blockquote>伯顿博士说，这些反应包括头痛、发烧和关节僵硬，应该与高剂量加强剂的潜在益处相平衡。</blockquote></p><p> Moderna also tested other experimental booster shots that target older variants, including Delta, and found they provided a comparable boost to antibody levels against Omicron as its original vaccine booster shot.</p><p><blockquote>Moderna 还测试了其他针对旧变种（包括 Delta）的实验性加强注射，发现它们对奥密克戎病毒的抗体水平的增强作用与其原始疫苗加强注射相当。</blockquote></p><p> Pfizer and BioNTech said a third dose of their Covid-19 vaccine increased neutralizing antibodies against Omicron compared with just two doses.</p><p><blockquote>辉瑞和BioNTech表示，与仅接种两剂相比，第三剂新冠肺炎疫苗增加了针对奥密克戎的中和抗体。</blockquote></p><p> Given the speed of Omicron’s spread, Moderna said its near-term priority will be to continue making booster shots of its original vaccine available.</p><p><blockquote>鉴于奥密克戎病毒的传播速度，Moderna公司表示，其近期的首要任务将是继续提供原有疫苗的加强注射。</blockquote></p><p> It said it would keep working on an Omicron-specific booster shot, in case it is needed. Moderna expects to start clinical trials of an Omicron-specific booster in early 2022.</p><p><blockquote>该公司表示，如果需要的话，将继续研发针对奥密克戎的加强注射。Moderna 预计将于 2022 年初开始奥密克戎特异性增强剂的临床试验。</blockquote></p><p> The new data on Moderna’s booster and Omicron came from lab tests that mix blood samples from vaccinated people with an engineered virus that resembles the Omicron variant. The tests were conducted at Duke University Medical Center labs that were established by the National Institute of Allergy and Infectious Diseases, Moderna said.</p><p><blockquote>有关 Moderna 加强剂和奥密克戎的新数据来自实验室测试，该测试将接种疫苗者的血液样本与一种类似奥密克戎变种的工程病毒混合在一起。Moderna说，这些测试是在杜克大学医学中心实验室进行的，该实验室由国家过敏和传染病研究所建立。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/moderna-says-covid-19-booster-dose-works-against-omicron-variant-in-lab-tests-11639994403?mod=hp_lead_pos2\">WSJ</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.wsj.com/articles/moderna-says-covid-19-booster-dose-works-against-omicron-variant-in-lab-tests-11639994403?mod=hp_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141595302","content_text":"ModernaInc. said a third dose of its Covid-19 vaccine increased immune responses against the Omicron coronavirus variant compared with two doses in lab tests, signaling the shot could still offer protection despite the variant’s mutations.\nThe findings, reported by Moderna on Monday, were the latest positive—though preliminary—results from lab tests suggesting boosters can protect against the worrisome new strain.\nThe Cambridge, Mass., company said the authorized dosage of its booster shot increased levels of immune-system agents known as neutralizing antibodies against Omicron about 37 times more than pre-boost levels.\nNeutralizing antibodies are among the first soldiers that the immune system deploys to battle invaders like the coronavirus.\n“What we showed is when you boost, you get a good brisk increase in antibody levels and they would be correlated with protection,” Moderna Chief Medical Officer Paul Burton said in an interview.\nThe authorized booster shot is half the dose level used for each of the first two shots of the vaccine.\nTogether with similar results from lab testing by Pfizer Inc.and partner BioNTech SE,Moderna’s findings suggest Covid-19 vaccines designed to fight the virus strain that was predominant during 2020may still hold up well against variants such as Omicron that are significantly mutated.\nYet people would have to get a booster shot on top of the primary series of vaccinations to gain the protection.\nWhen Omicron emerged, researchers and health authorities expressed concern that the variant could evade vaccines because it has many mutations to the spike protein targeted by the shots.\nAdding to their fears was research indicating that Omicron is less susceptible to two doses of Moderna’s and other Covid-19 vaccines.\nLab-test results released last week by a team of researchers from Moderna, the National Institute of Allergy and Infectious Diseases and Duke University showed that two doses of Moderna’s vaccine had significantly reduced neutralization activity against Omicron.\nThe findings from Pfizer-BioNTech and Moderna are based on lab tests, not the clinical trials in volunteers that are considered more definitive.\nModerna disclosed its booster results, which haven’t been peer reviewed and published in a scientific journal, in a news release. The company plans to share the data with government health officials.\nThe Omicron variant was identified in late November in southern Africa and has now spread to many countries, including the U.S.\nEarly studies suggest it spreads faster and reinfects people more easily than other variants and it evades vaccine-induced antibodies to a greater degree. It isn’t known yet whether Omicron causes more or less severe Covid-19.\nThe new data may reinforce calls by public-health officials for vaccinated people to get booster shots. In the U.S., only about 29.5% of fully vaccinated people have received booster doses, according to the Centers for Disease Control and Prevention.\nModerna also found that using a full dose for the third shot packed a more powerful punch than the authorized booster dose. A third full dose increased neutralizing antibodies against Omicron about 83 times more than pre-boost levels.\nDr. Burton said government regulators may want to consider recommending the higher-dose boosters to increase protection, at least among people at higher risk of more severe Covid-19.\nHowever, in a separate study, Moderna said people receiving the higher-dose booster had more frequent adverse reactions than those who received the lower dose.\nDr. Burton said the reactions include headache, fever and joint stiffness and should be balanced against the potential benefits of a higher-dose booster.\nModerna also tested other experimental booster shots that target older variants, including Delta, and found they provided a comparable boost to antibody levels against Omicron as its original vaccine booster shot.\nPfizer and BioNTech said a third dose of their Covid-19 vaccine increased neutralizing antibodies against Omicron compared with just two doses.\nGiven the speed of Omicron’s spread, Moderna said its near-term priority will be to continue making booster shots of its original vaccine available.\nIt said it would keep working on an Omicron-specific booster shot, in case it is needed. Moderna expects to start clinical trials of an Omicron-specific booster in early 2022.\nThe new data on Moderna’s booster and Omicron came from lab tests that mix blood samples from vaccinated people with an engineered virus that resembles the Omicron variant. The tests were conducted at Duke University Medical Center labs that were established by the National Institute of Allergy and Infectious Diseases, Moderna said.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2665,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":30,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/693650502"}
精彩评论